Gabriella Ortore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3133558/publications.pdf

Version: 2024-02-01

471509 552781 44 728 17 26 citations h-index g-index papers 47 47 47 1176 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis. Journal of Medicinal Chemistry, 2006, 49, 984-994.	6.4	93
2	Analysis of Human Carbonic Anhydrase II:  Docking Reliability and Receptor-Based 3D-QSAR Study. Journal of Chemical Information and Modeling, 2007, 47, 515-525.	5.4	39
3	Docking of Hydroxamic Acids into HDAC1 and HDAC8: A Rationalization of Activity Trends and Selectivities. Journal of Chemical Information and Modeling, 2009, 49, 2774-2785.	5.4	37
4	NewN-n-Propyl-Substituted 3-Aryl- and 3-Cyclohexylpiperidines as Partial Agonists at the D4Dopamine Receptor. Journal of Medicinal Chemistry, 2003, 46, 161-168.	6.4	36
5	Novel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural Analysis. PLoS ONE, 2009, 4, e6290.	2.5	34
6	Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. Il Farmaco, 2004, 59, 25-31.	0.9	33
7	Pharmacophore Based Receptor Modeling:Â The Case of Adenosine A3Receptor Antagonists. An Approach to the Optimization of Protein Models. Journal of Medicinal Chemistry, 2006, 49, 4085-4097.	6.4	32
8	Study on Affinity Profile toward Native Human and Bovine Adenosine Receptors of a Series of 1,8-Naphthyridine Derivatives. Journal of Medicinal Chemistry, 2004, 47, 3019-3031.	6.4	31
9	Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes. Journal of Medicinal Chemistry, 2006, 49, 5001-5012.	6.4	27
10	Homology Modeling and Receptor-Based 3D-QSAR Study of Carbonic Anhydrase IX. Journal of Chemical Information and Modeling, 2007, 47, 2253-2262.	5.4	26
11	Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 7749-7758.	3.0	25
12	Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach. Journal of Chemical Information and Modeling, 2013, 53, 2538-2547.	5.4	24
13	Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode. Journal of Chemical Information and Modeling, 2018, 58, 794-815.	5.4	22
14	Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure:Â Role of the Phenol-Type Pseudocycle in the Binding Process. Journal of Medicinal Chemistry, 2003, 46, 4032-4042.	6.4	20
15	A Theoretical Study To Investigate D2DAR/D4DAR Selectivity:  Receptor Modeling and Molecular Docking of Dopaminergic Ligands. Journal of Medicinal Chemistry, 2006, 49, 1397-1407.	6.4	18
16	Multitemplate Alignment Method for the Development of a Reliable 3D-QSAR Model for the Analysis of MMP3 Inhibitors. Journal of Chemical Information and Modeling, 2009, 49, 1715-1724.	5.4	18
17	A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by Using a Pharmacophoreâ€based Approach. Molecular Informatics, 2016, 35, 434-439.	2.5	18
18	Targeting Different Transthyretin Binding Sites with Unusual Natural Compounds. ChemMedChem, 2016, 11, 1865-1874.	3.2	16

#	Article	IF	Citations
19	Adenosine receptor modelling. A1/A2a selectivity. European Journal of Medicinal Chemistry, 2006, 41, 321-329.	5.5	15
20	Synthesis, molecular docking and binding studies of selective serotonin transporter inhibitors. European Journal of Medicinal Chemistry, 2011, 46, 825-834.	5.5	15
21	Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands. Journal of Medicinal Chemistry, 2022, 65, 9918-9938.	6.4	15
22	Interaction of aminoadamantane derivatives with the influenza A virus M2 channel-Docking using a pore blocking model. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4182-4187.	2.2	12
23	Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 1511-1515.	3.0	12
24	Focus on Human Monoamine Transporter Selectivity. New Human DAT and NET Models, Experimental Validation, and SERT Affinity Exploration. ACS Chemical Neuroscience, 2020, 11, 3214-3232.	3.5	12
25	1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4604-4610.	2.2	11
26	Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 34-47.	5.2	11
27	Virtual screening and crystallographic studies reveal an unexpected \hat{I}^3 -lactone derivative active against MptpB as a potential antitubercular agent. European Journal of Medicinal Chemistry, 2022, 234, 114235.	5.5	11
28	Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 223-226.	2.2	8
29	Computational Studies on Translocator Protein (TSPO) and its Ligands. Current Topics in Medicinal Chemistry, 2012, 12, 352-359.	2.1	8
30	Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties. European Journal of Medicinal Chemistry, 2002, 37, 585-594.	5.5	6
31	Identification of Transthyretin Fibril Formation Inhibitors Using Structureâ€Based Virtual Screening. ChemMedChem, 2017, 12, 1327-1334.	3.2	6
32	Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives. Journal of Medicinal Chemistry, 2022, 65, 7118-7140.	6.4	6
33	Molecular Modeling of Adenosine Receptors. Methods in Enzymology, 2013, 522, 37-59.	1.0	5
34	Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2021, 22, 3488.	4.1	5
35	Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands. Arkivoc, 2006, 2006, 83-94.	0.5	4
36	Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion. Il Farmaco, 2003, 58, 707-714.	0.9	3

#	Article	lF	CITATIONS
37	Structure-Based Virtual Screening: Identification of Novel CB2 Receptor Ligands. Letters in Drug Design and Discovery, 2007, 4, 15-19.	0.7	3
38	Different Binding Modes of Structurally Diverse Ligands for Human D3DAR. Journal of Chemical Information and Modeling, 2010, 50, 2162-2175.	5.4	3
39	From Anti-infective Agents to Cancer Therapy: A Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives. Medicinal Chemistry, 2022, 18, 249-259.	1.5	2
40	CB1 receptor binding sites for NAM and PAM: A first approach for studying, new nâ€'butylâ€'diphenylcarboxamides as allosteric modulators. European Journal of Pharmaceutical Sciences, 2022, 169, 106088.	4.0	2
41	Synthesis and Evaluation of Monoaryl Derivatives as Transthyretin Fibril Formation Inhibitors. Pharmaceutical Chemistry Journal, 2022, 56, 38-47.	0.8	2
42	Synthesis and COX-2 Inhibitory Properties of N-Phenyl- and N-Benzyl-Substituted Amides of 2-(4-Methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic Acid and of Their Pyrazole, Thiophene and Isoxazole Analogues ChemInform, 2004, 35, no.	0.0	1
43	Synthesis and Prostaglandin Synthase Inhibitory Activity of New Aromatic O-Alkyloxime Ethers Substituted with Methylsulfonamido or Methylsulfonyl Groups on Their Aliphatic Portion ChemInform, 2004, 35, no.	0.0	0

EDITORIAL [Hot Topic: Transthyretin: A Small Protein in the Big World of Amyloidoses (Guest Editors:) Tj ETQq0 0 0 rgBT /Overlock 10 Td